Skip to main content
SpringerLink
Log in

Psychopharmaka

  • Chapter
Arzneiverordnungs-Report 2008

Zusammenfassung

Die Verordnungsstruktur der Psychopharmaka hat sich in den letzten 10 Jahren auffällig verändert. Die Verordnungen der früher führenden Tranquillantien sind seit vielen Jahren rückläufig. Umgekehrt haben sich die Antidepressivaverordnungen in dieser Zeit mehr als verdoppelt. Dieser Trend setzte sich 2007 durch einen Anstieg bei den selektiv wirkenden Antidepressiva fort, der teilweise die 20%-Marke überschritt. Vergleichsweise ist die Verordnung von Neuroleptika im Bereich der atypischen Neuroleptika deutlich weniger angestiegen. Beträchtlich zugenommen haben wiederum die Verordnungen von Psychostimulanzien einschließlich des Atomoxetins.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity (2004): Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27: 596–601.

    Article  Google Scholar 

  • Anonym (2003): Lithium-Therapie bei der manisch-depressiven Erkrankung: Immer noch der Standard? Arzneimittelbrief 37: 49–51.

    Google Scholar 

  • Anonym (2004): Escitalopram. Un isomère du Citalopram, sans aucun avantage thérapeutique. Rev Prescrire 24: 325–328.

    Google Scholar 

  • Anonym (2005a): Antidepressiva: lebensgefährliche Placebos? Arznei-telegramm 36: 45–47.

    Google Scholar 

  • Anonym (2005b): Aripiprazole. Prescrire International 14: 163.

    Google Scholar 

  • Anonym (2006a): Duloxetine: new indication. Depression and diabetic neuropathy: too many adverse effects. Prescrire Int 15: 168–172.

    Google Scholar 

  • Anonym (2006b): Neuroleptics: increased rate of venous thromboembolic events. Rev. Prescrire Internat 15: 224.

    Google Scholar 

  • Anonym (2008a): Kinder: Neuroleptikagebrauch steigt. Arzneitelegramm 39: 69–70.

    Google Scholar 

  • Anonym (2008b): Desvenlafaxine (Pristiq). Biol Ther Psychiatry 31: 21–22.

    Google Scholar 

  • Arvanitis LA, Miller BG (1997): Multiple fixed doses of „Seroquel“ (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 42: 233–246.

    Article  CAS  PubMed  Google Scholar 

  • Arzneimittelkommission der deutschen Ärzteschaft (Hrsg) (2003): Empfehlungen zur Therapie von Angst-und Zwangsstörungen. 2. Aufl. Sonderheft Arzneiverordnung in der Praxis.

    Google Scholar 

  • Arzneimittelkommission der deutschen Ärzteschaft (Hrsg) (2006a): Empfehlungen zur Therapie der Depression. 2. Aufl. Sonderheft Arzneiverordnung in der Praxis, im Druck.

    Google Scholar 

  • Arzneimittelkommission der deutschen Ärzteschaft (2006b): Hypersexualität unter Aripiprazol. Deutsches Ärzteblatt 103: A3518.

    Google Scholar 

  • Arzneimittelkommission der deutschen Ärzteschaft (2008): Stellenwert von Antidepressiva in der Depressionsbehandlung. Arzneiverordnung in der Praxis 35: 42–43.

    Google Scholar 

  • Baghai TC, Volz HP, Möller HJ (2006): Drug treatment of depression in the 2000s: An overview of achievements in the last 10 years and future possibilities. World J Biol Psychiatry 7: 198–222.

    Article  PubMed  Google Scholar 

  • Barbui C, Hotopf M (2001): Amitriptyline vs. the rest: still the leading antidepressant after 40 years of randomised controlled trials. Brit J Psychiatry 178: 129–144.

    Article  CAS  Google Scholar 

  • Barbui C, Hotopf M, Freemantle N, Boynton J, Churchill R, Eccles MP et al (2000): Selective serotonin reuptake inhibitors versus tricyclic and heterocyclic antidepressants: comparison of drug adherence. Cochrane Database Syst Rev 2000(4): CD002791.

    Google Scholar 

  • Bauer M, Dopfner S (1999): Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies. J Clin Psychopharmacol 19: 427–434.

    Article  CAS  PubMed  Google Scholar 

  • Bauer M, Grof P, Müller-Oerlinghausen B (eds.) (2006) Lithium in Neuropsychiatry: The Comprehensive Guide. Taylor & Francis Books Ltd, Abingdon, (in print)

    Google Scholar 

  • Bauer M, Whybrow PC, Angst C, Verslani M, Möller H-J (2002): World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for biological treatment of unipolar depressive disorders, Part 1: Acute and continuation treatment of major depressive disorder. World J Biol Psychiatry 3: 5–43.

    Article  PubMed  Google Scholar 

  • Baumann P (1996): Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet 31: 444–469.

    Article  CAS  PubMed  Google Scholar 

  • Baumann P, Zullino DF, Eap CB (2002): Enantiomers’ potential in psychopharmacology — a critical analysis with special emphasis on the antidepressant escitalopram. Eur Neuropsychopharmacol 12: 433–444.

    Article  CAS  PubMed  Google Scholar 

  • Benkert O, Szegedi A, Kohnen R (2000): Mirtazapine compared with paroxetine in major depression. J Clin Psychiatry 61: 656–663.

    Article  CAS  PubMed  Google Scholar 

  • Becker W (2008): Langzeitmedikation schiziphrener Psychosen in einem psychiatrischen Pflegeheim. Sozialpsychiatr Informationen 38: 28–32.

    Google Scholar 

  • Biddle L, Brock A, Brookes ST, Gunnell D (2008): Suicide rates in young men in England and Wales in the 21st century. Brit Med J 336: 539–542.

    Article  PubMed  Google Scholar 

  • Bielski RJ, Ventura D, Chang CC (2004): A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. Clin Psychiatry 65: 1190–1196.

    Article  CAS  Google Scholar 

  • Bockting CL, ten Doessefate MC, Spijker J et al. (2008): Confirmation and maintenance use of antidepressants in recurrent depression. Psychother Psychosom 77: 17–26.

    Article  PubMed  Google Scholar 

  • Bschor T (2008): Antidepressiva: Mythen und Fakten. Sozialpsychiatr Informationen 38: 24–28.

    Google Scholar 

  • Bschor T, Baethge C (2008): Wechsel des Antidepressivums. In: Bschor T (Hrsg): Behandlungsmanual therapieresistenter Depressionen. Hohlhammer Verlag, Stuttgart.

    Google Scholar 

  • Carriere P, Bonhomme D, Lemperiere T (2000): Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group). Eur Psychiatry 15: 321–329.

    Article  CAS  PubMed  Google Scholar 

  • Carter CS, Mulsant BH, Sweet RA, Maxwell RA, Coley K et al (1995): Risperidone use in a teaching hospital during its first year after market approval: economic and clinical implications. Psychopharmacol Bull 31: 719–725.

    CAS  PubMed  Google Scholar 

  • Chick J, Howlett H, Morgan MY, Ritson B (2000): United Kingdom Multicentre Acamprosate Study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol. Alcohol Alcohol 35: 176–187.

    CAS  PubMed  Google Scholar 

  • Chouinard G, Jones B, Remington G, Bloom D, Addington D et al (1993): A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 13: 25–40.

    Article  CAS  PubMed  Google Scholar 

  • Cipriani A, Pretty H, Hawton K, Geddes JR (2005): Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. Am J Psychiatry 162: 1805–1819.

    Article  PubMed  Google Scholar 

  • Correll CU, Leucht S, Kane JM (2004): Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 161:414–425.

    Article  PubMed  Google Scholar 

  • Croissant B, Mann K (2004): Pharmakologische Rückfallprophylaxe bei Alkoholabhängigkeit. Psychoneuro 30: 30–36.

    Article  Google Scholar 

  • Davis JM, Chen N, Glick ID (2003): A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 60: 553–564.

    Article  CAS  PubMed  Google Scholar 

  • Di Carlo G, Borreli F, Ernst E, Izzo AA (2001): St Johns wort: Prozac from the plant kingdom. Trends Pharmacol Sci 22: 292–297.

    Article  PubMed  Google Scholar 

  • Dinan TG (2002): Lithium in bipolar mood disorder. Evidence suggests that lithium should still be first choice for prophylactic treatment. Brit Med J 324: 988–989.

    Article  Google Scholar 

  • Donovan S, Clayton A, Beeharry M, Jones S, Kirk C, Waters K et al (2000): Deliberate self-harm and antidepressant drugs. Investigation of a possible link. Br J Psychiatry 177: 551–556.

    Article  CAS  PubMed  Google Scholar 

  • Einarson TR, Arikian SR, Casciano J, Doyle JJ (1999): Comparison of extended-release venlafaxine, selective serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression: a meta-analysis of randomized controlled trials. Clin Ther 21: 296–308.

    Article  CAS  PubMed  Google Scholar 

  • Elliger TJ, Trott GE, Nissen G (1990): Prevalence of psychotropic medication in childhood and adolescence in the Federal Republic of Germany. Pharmacopsychiatry 23: 38–44.

    Article  CAS  PubMed  Google Scholar 

  • EMEA (2005): Scientific Discussion vom 27.1.2005. Im Internet unter: www.emea.eu.int/humandocs/Humans/EPAR/cymbalta/cymbalta.htm

    Google Scholar 

  • Ernst CL, Goldberg JF (2004): Antisuicide properties of psychotropic drugs: a critical review. Harv Rev Psychiatry 12: 14–41.

    PubMed  Google Scholar 

  • Food and Drug Administration (FDA) (2007): FDA proposes new warnings about suicidal thinking, behaviour in young adults to take antidepressant medications. http://www.fda.gov/bbs/topics/NEWS/2007/NEW01624.html.

    Google Scholar 

  • Food and Drug Administration (FDA) (2008): Drug Safety Newsletter 1: 22–24.

    Google Scholar 

  • Franchini L, Zanardi R, Gasperini M, Perez J, Smeraldi E (1996): Fluvoxamine and lithium in long-term treatment of unipolar subjects with high recurrence rate. J Affect Disord 38: 67–69.

    Article  CAS  PubMed  Google Scholar 

  • Frank E, Kupfer DJ, Perel JM (1990): Three-years outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 47: 1093–1099.

    CAS  PubMed  Google Scholar 

  • Gaebel W, Riesbeck M, Wölwer W, Klimke A, Eickhoff M, von Wilmsdorff M, Jockers-Scherübl MC, Kühn KU, Lemke M, Bechdolf A, Bender S, Degner D, Schlösser R, Schmidt LG, Schmitt A, Jäger M, Buchkremer G, Falkai P, Klingberg S, Köpcke W, Maier W, Häfner H, Ohmann C, Salize HJ, Schneider F, Möller HJ; German Study Group on First-Episode Schizophrenia (2007): Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia. J Clin Psychiatry 68: 1763–1774.

    Article  CAS  PubMed  Google Scholar 

  • Gaynes BN, Rush AJ, Trivedi MH, Wisniewski SR, Spencer D, Fava M (2008): The STAR*D study: treating depression in the real world. Cleve Clin J Med. 75:57–66

    Article  PubMed  Google Scholar 

  • Geddes J, Freemantle N, Harrison P et al (2000): Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. Brit Med J 321: 1371–1376.

    Article  CAS  PubMed  Google Scholar 

  • Geddes JR, Freemantle N, Mason J, Eccles MP, Boynton J (2001): SSRIs versus other antidepressants for depressive disorder. Update Software Ltd Oxford, The Cochrane Library-Issue 1.

    Google Scholar 

  • Gentile S (2007): Atypical antipsychotics for the treatment of bipolar disorders. CNS Drugs 21: 367–387.

    Article  CAS  PubMed  Google Scholar 

  • Gibbons RD, Brown CH, Hur K, Marcus SM, Baumikh DK, Erkenmann JJ (2007): Early evidence on the effects of regulators’ suicidality warnings on prescriptions and suicide in children and adolescents. Am J Psychiatry 164: 1356–1363.

    Article  PubMed  Google Scholar 

  • Giles J (2007): Court case to reclaim confidential data. Nature 446: 838–839.

    Article  CAS  PubMed  Google Scholar 

  • Goodnick PJ, Barrios CA (2001): Use of olanzapine in non-psychotic psychiatric disorders. Expert Opin Pharmacother 2: 667–680.

    Article  CAS  PubMed  Google Scholar 

  • Goodwin FK, Fireman B, Simon GE, Hunkeler EM, Lee J, Revicki D (2003): Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA 290: 1467–1473.

    Article  CAS  PubMed  Google Scholar 

  • Goodwin GM, Bowden CL, Calabrese JR, Grunze H, Kasper S et al (2004): A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry 65: 432–441.

    Article  CAS  PubMed  Google Scholar 

  • Greil W, Ludwig-Mayerhofer W, Erazo N, Engel RR, Czernik A et al (1996): Comparative efficacy of lithium and amitriptyline in the maintenance treatment of recurrent unipolar depression: a randomised study. J Affect Disord 40: 179–190.

    Article  CAS  PubMed  Google Scholar 

  • Guelfi JD, Ansseau M, Timmerman L, Korsgaard S (2001): Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features. J Clin Psychopharmacol 21: 425–431.

    Article  CAS  PubMed  Google Scholar 

  • Gunnel D, Saperia J Ashby D (2005): Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo-controlled, randemised controlled trials of newer antidepressants. Brit Med J 330: 385–389.

    Article  Google Scholar 

  • Healy D (2003): Lines of evidence on the risks of suicide with selective serotonin reuptake inhibitors. Psychother Psychosom 72: 71–79.

    Article  PubMed  Google Scholar 

  • Healy D (2006): The latest mania: selling bipolar disorders. PLoS Med 3: e185.

    Article  PubMed  Google Scholar 

  • Henderson DC, Doraiswamy PM (2008): Prolactin-related and metabolic adverse effects of atypical antipsychotic agents. J Clin Psychiatry 69Suppl 1: 32–44.

    CAS  PubMed  Google Scholar 

  • Hirschfeld RM, Kasper S (2004): A review of the evidence for carbamazepine and oxcarbazepine in the treatment of bipolar disorder. Int J Neuropsychopharmacol. 7: 507–522.

    Article  CAS  PubMed  Google Scholar 

  • Hoffmann F, Glaeske D, Scharffetter W (2006): Zunehmender Hypnotikaverbrauch auf Privatrezepten in Deutschland. Sucht 52: 360–366.

    Google Scholar 

  • Jacob CP, Philipsen A, Ebert D, Deckert J (2008): Multimodale Therapie der Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung im Erwachsenenalter. Nervenarzt (im Druck; DOI 10.1007/s00115-008-2510-6).

    Google Scholar 

  • Jans T, Kreiker S, Warnke A (2008): Multimodale Therapie der Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung im Kindesalter. Nervenarzt (im Druck; DOI 10.1007/s00115-008-2512-4).

    Google Scholar 

  • Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A, Lewis SW (2006): Randomized controlled trial of the effect on Quality of Life of second-vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 63: 1079–1087.

    Article  CAS  PubMed  Google Scholar 

  • Jureidini JN, Doecke CJ, Mansfield PR, Haby MM, Menkes DB, Tonkin AL (2004): Efficacy and safety of antidepressants for children and adolescents. BMJ 328: 879–883.

    Article  CAS  PubMed  Google Scholar 

  • Juurlink DN, Mamdani MM, Kopp A, Redelmeier DA (2006): The risk of suicide with selective serotonin reuptake inhibitors in the elderly. Am J Psychiatry 163: 813–821.

    Article  PubMed  Google Scholar 

  • Kane J, Honigfeld G, Singer J, Meltzer H (1988): Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 45: 789–796.

    CAS  PubMed  Google Scholar 

  • Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K (2003): Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 160: 1125–1132.

    Article  PubMed  Google Scholar 

  • Kappler J, Menges C, Ferbert A, Ebel H (1994): Schwere „Spät“dystonie nach „Neuroleptanxiolyse“ mit Fluspirilen. Nervenarzt 65: 66–68.

    CAS  PubMed  Google Scholar 

  • Kassenärztliche Bundesvereinigung (2006): Wirkstoff aktuell: Quetiapin (Seroquel®). Ausgabe 05/2006.

    Google Scholar 

  • Kassenärztliche Bundesvereinigung (2007): Bekanntmachungen: Rahmenvorgaben nach § 84 Absatz 7 SGB V und Vereinbarung nach § 84 Abs. 7a SGB V — Arzneimittel — für das Jahr 2007 vom 19. September 2006. Dtsch Ärztebl 104: A 69–A 72.

    Google Scholar 

  • Kassenärztliche Bundesvereinigung (2008): Wirkstoff aktuell: Venlafaxin (Trevilor®). Ausgabe 03/2008.

    Google Scholar 

  • Kessler RC, Demier O, Frank RG, Olfson M, Pincus HA, Walters EE et al (2005): Prevalence and treatment of mental disorders, 1990 to 2003. N Engl J Med 352:2515–2523.

    Article  CAS  PubMed  Google Scholar 

  • Kimko HC, Cross JT, Abernethy DR (1999): Pharmacokinetics and clinical effectiveness of methylphenidate. Clin Pharmakokinet 37: 457–470.

    Article  CAS  Google Scholar 

  • Kirsch I, Deacon BJ, Huedo-Medina TB et al. (2008): Initial severity and antidepressant benefit: a meta-analysis of data submitted to the Food and Drug Administration. PloS Med 5: e45.

    Article  PubMed  Google Scholar 

  • Knopf H, Melchert H-U (2003): Bundes-Gesundheitssurvey: Arzneimittelgebrauch. Robert-Koch-Institut Berlin (Hrsg).

    Google Scholar 

  • Kornhuber J (1994): Potentielle Antipsychotica mit neuartigen Wirkmechanismen. In: Riederer P, Laux G, Pöldinger W (Hrsg): Neuropsychopharmaka, Bd. 4: Neuroleptica. Springer-Verlag, Wien New York, S. 185–196.

    Google Scholar 

  • Lapierre YD (1989): A review of trimipramine 30 years of clinical use. Drugs 38(suppl 1): 17–24.

    Article  PubMed  Google Scholar 

  • Lesch OM, Riegler A, Gutierrez K, Hertling I, Ramskogler K, Semler B et al (2001): The European acamprosate trials. Conclusions for research and therapy. J Biomed Sci 8: 89–95.

    Article  CAS  PubMed  Google Scholar 

  • Leucht S, Barnes TR, Kissling W, Engel RR, Correll C, Kane JM (2003a): Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 160: 1209–1222.

    Article  PubMed  Google Scholar 

  • Leucht S, Wahlbeck K, Hamann J, Kissling W (2003b): New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and metaanalysis. Lancet 361: 1581–1589.

    Article  CAS  PubMed  Google Scholar 

  • Leucht S, Komossa K (2006): Methodik und kritische Interpretation psychopharmakologischer Schizophreniestudien. Psychopharmakotherapie 13: 231–240.

    Google Scholar 

  • Licino J, Wong M-L (2005): Depression, antidpressants and sucidality: a critical appraisal. Nature Rev. Drug Disc. 4, 165–171.

    Article  CAS  Google Scholar 

  • Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators (2005): Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209–1233.

    Article  CAS  PubMed  Google Scholar 

  • Linde K, Berner M, Egger M, Mulrow C (2005): St Johns wort for depression: metaanalysis of randomised controlled trials. Br J Psychiatry 186: 99–107.

    Article  PubMed  Google Scholar 

  • MacGillivray S, Arroll B, Hatcher S, Ogston S, Reid I, Sullivan F et al (2003): Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and metaanalysis. Brit Med J 326: 1014–1019.

    Article  CAS  PubMed  Google Scholar 

  • Macritchie KAN, Geddes MR, Scott J, Haslam DRS, Goodwin GM (2001): Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorders. Cochrane Review. In: The Cochrane Library Issue 3. Oxford, Updated Software.

    Google Scholar 

  • Marder SR, Meibach RC (1994): Risperidone in the treatment of schizophrenia. Am J Psychiatry 151: 825–835.

    CAS  PubMed  Google Scholar 

  • McCue RE, Waheed R, Urcuyo L et al. (2006): Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia. Brit J Psychiatry 189: 433–440.

    Article  Google Scholar 

  • McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, Swartz MS, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK; CATIE Investigators (2006): Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 163: 600–610.

    Article  PubMed  Google Scholar 

  • Molina BSG, Florey K, Hinshaw SP, Greiner, AR, Arnold E, Swanson JM, Hechtman L, Jensen PS, Vitiello B, Hoza B, Pelham WE, Elliot GR, Wells KC, Abikoff HB, Gibbons RD, Marcus S, Conners CK, Epstein JN, Greenhill LL, March JS, Newcorn JH, Severe JB, Wigal T (2007): Delinquent behavior and emerging substance use in the MTA at 36 months: Prevalence, course, and treatment effects. J Am Acad Child Adolesc Psychiatry 46: 1028–1040.

    Article  PubMed  Google Scholar 

  • Möller H-J (1999): Atypical neuroleptics: a new approach in the treatment of negative symptoms. Eur Arch Psychiatry Clin Neurosci 249(Suppl 4): 99–107.

    PubMed  Google Scholar 

  • Möller H-J, Volz HP, Reimann IW, Stoll KD (2001): Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group. J Clin Psychopharmacol 21: 59–65.

    Article  PubMed  Google Scholar 

  • Moncrieff J (2001): Are antidepressants overrated? A review of methodological problems in antidepressant trials. J Nerv Ment Dis 189: 288–295.

    Article  CAS  PubMed  Google Scholar 

  • Moncrieff J (2008): Steht die Psychiatrie zum Verkauf an? Sozialpsychiatr Informationen 38: 8–18.

    Google Scholar 

  • Moncrieff J, Kirsch I (2005): Efficacy of antidepressants in adults. BMJ 331: 155–157.

    Article  PubMed  Google Scholar 

  • Montgomery SA, Roberts A, Patel AG (1994): Placebo-controlled efficacy of antidepressants in continuation treatment. Int Clin Psychopharmacology 9: 49–53.

    Article  Google Scholar 

  • Montgomery S, Ferguson JM, Schwartz GE (2003): The antidepressant efficacy of reboxetine in patients with severe depression. J Clin Psychopharmacol 23: 45–50.

    Article  CAS  PubMed  Google Scholar 

  • Moreno C, Laje G, Blanco C, Jiang H, Schmidt AB, Olfron M (2007): National trends in the outpatient diagnosis and treatment of bipolar disorders in youths. Arch Gen Psychiatry 64: 1032–1039.

    Article  PubMed  Google Scholar 

  • MTA Cooperative Group (1999): A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiat 56: 1073–1086.

    Article  Google Scholar 

  • Müller-Oerlinghausen B (2001): Abhängigkeit und Mißbrauch von Substanzen. Dtsch Ärztebl 98:A1625–A1627.

    Google Scholar 

  • Müller-Oerlinghausen B, Berghöfer A (1999): Antidepressants and suicidal risk. J Clin Psychiatry 60(suppl 2): S94–S99.

    Google Scholar 

  • Müller-Oerlinghausen B, Berghöfer A, Ahrens B (2003): The antisuicidal and mortality-reducing effect of lithium prophylaxis: consequences for guidelines in clinical psychiatry. Can J Psychiatry 48: 433–439.

    PubMed  Google Scholar 

  • Naber D, Dose M (2006): Pro und Kontra: Grundsätzlicher Vorrang für Atypica. Psychiatr Praxis 32: 163–166.

    Google Scholar 

  • Nemeroff CB, Schatzberg AF, Goldstein DJ, Detke MJ, Mallinckrodt C, Lu Y, Tran PV (2002): Duloxetine for the treatment of major depressive disorder. Psychopharmacol Bull 36: 106–132.

    PubMed  Google Scholar 

  • Nissen SE (2006): ADHD drugs and cardiovascular risk. N Engl J Med 354: 1445–1448.

    Article  CAS  PubMed  Google Scholar 

  • Oeljeschläger B, Müller-Oerlinghausen B (2004): Wege zur Optimierung der individuellen antidepressiven Therapie. Deutsches Ärzteblatt 101: A 1337–1340.

    Google Scholar 

  • Perlis RH, Perlis CS, Wu Y, Hwang M, Nierenberg AA (2005): Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry. Am J Psychiatry 162: 1957–1960.

    Article  PubMed  Google Scholar 

  • Philipsen A, Heßlinger B, van Elst LT (2008): Aufmerksamkeitsdefizit-Hyperaktivitätsstörung im Erwachsenenalter. Diagnostik, Ätiologie und Therapie. Dtsch Ärztebl 105:311–317.

    Google Scholar 

  • Remschmidt H, Global ADHD Working Group (2005): Global consensus on ADHD/HKD. Eur Child Adolesc Psychiatry 14: 127–137.

    Article  PubMed  Google Scholar 

  • Rickeis K, Rynn M (2002): Pharmacotherapy of generalized anxiety disorder. J Clin Psychiatry 63(Suppl 14): 9–16.

    Google Scholar 

  • Riederer P, Laux G, Pöldinger W (Hrsg) (1993): Neuropsychopharmaka Bd. 3 Antidepressiva und Phasenprophylaktika. Springer-Verlag, Wien New York.

    Google Scholar 

  • Rosenheck RA, Leslie DL, Sindelar JL, Miller EA, Tariot PN, Dagerman KS, Davis SM, Lebowitz BD, Rabins P, Hsiao JK, Lieberman JA, Schneider LS; Clinical Antipsychotic Trial of Intervention Effectiveness-Alzheimer’s Disease (CATIE-AD) investigators (2007): Cost-benefit analysis of second-generation antipsychotics and placebo in a randomized trial of the treatment of psychosis and aggression in Alzheimer disease. Arch Gen Psychiatry 64: 1259–1268.

    Article  PubMed  Google Scholar 

  • Royal College of Psychiatrists, British Psychological Society (2006): Schizophrenia. Full national clinical guideline on core interventions in primary and secondary care. Internet: http://guidance.nice.org.uk/CGl/guidance/pdf/English

    Google Scholar 

  • Safer DJ (2000): Are stimulants overprescribed for youths with ADHD? Ann Clin Psychiatry 12: 55–62.

    CAS  PubMed  Google Scholar 

  • Sass H, Soyka M, Mann K, Zieglgansberger W (1996): Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry 53: 673–680.

    CAS  PubMed  Google Scholar 

  • Schlander M (2007): Aktuelle Daten zur medizinischen Versorgung von Kindern und Jugendlichen mit ADHS in Deutschland — Administrative Prävalenz, beteiligte Arztgruppen und Arzneimitteltherapie. Psychoneuro 33: 412–415.

    Article  Google Scholar 

  • Schöpf J, Müller-Oerlinghausen B (2005): Standardpräparate der Psychopharmakotherapie. Lithium. 2. Aufl. Springer-Verlag, Berlin Heidelberg New York

    Google Scholar 

  • Schou M (1998): Has the time come to abandon prophylactic lithium treatment? A review for clinicians. Pharmacopsychiatry 31: 210–215.

    Article  CAS  PubMed  Google Scholar 

  • Smith D, Dempster C, Glanville J, Freemantle N, Anderson I (2002): Efficacy and tole-rability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br Psychiatry 180: 396–404.

    Article  Google Scholar 

  • Snow V, Lascher S, Mottur-Pilson C, for the American College of Physicians-American Society of Internal Medicine (2000): Clinical guideline I. Pharmacological treatment of acute major depression and dysthymia. Ann Int Med 132: 739–742.

    Google Scholar 

  • Søndergård l; Lopez AG, Kessing LU (2008): Mood-stabilizing pharmacological treatment in bipolar disorder and risk of suicide. Bipol Dis 10: 87–94.

    Article  Google Scholar 

  • Spielmans GI (2008): Duloxetine does not relieve painful psychological symptoms in depression. A metaanalysis. Psychother Psychosom 77: 12–16.

    Article  PubMed  Google Scholar 

  • Stip E (2000): Novel antipsychotics: issues and controversies. Typicality of atypical neuroleptics. J Psychiatry Neurosci 25: 137–153.

    CAS  PubMed  Google Scholar 

  • Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK; CATIE Investigators (2006): Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 163: 611–622.

    Article  PubMed  Google Scholar 

  • Swanson J, Greenhill L, Wigal T, Kollins S, Stehli A, Davies M, Chuang S, Vitiello B, Skrobala A, Posner K, Abikoff H, Oatis M, McCracken J, McGough J, Riddle M, Ghuman J, Cunningham C, Wigal S (2006): Stimulant-related reductions of growth rates in the PATS. J Am Acad Child Adolesc Psychiatry 45: 1304–1313.

    Article  PubMed  Google Scholar 

  • Swartz MS, Stroup TS, McEvoy JP, Davis SM, Rosenheck RA, Keefe RS, Hsiao JK, Lieberman JA (2008): What CATIE Found: Results From the Schizophrenia Trial. Psychiatr Serv 59: 500–506.

    Article  PubMed  Google Scholar 

  • Szarfman A, Tonning JM, Levine JG, Doraiswamy PM (2006): Atypical antipsychotics and pituitary tumors: a pharmacovigilance study. Pharmacotherapy 26: 748–758.

    Article  CAS  PubMed  Google Scholar 

  • Tandon R, Jibson MD (2003): Efficacy of newer generation antipsychotics in the treatment of schizophrenia. Psychoneuroendocrinology 28: 9–26.

    Article  CAS  PubMed  Google Scholar 

  • Tandon R, Belmaker RH, Gattaz WF, Lopez-Ibor JJ Jr, Okasha A, Singh B, Stein DJ, Olie JP, Fleischhacker WW, Moeller HJ; Section of Pharmacopsychiatry, World Psychiatric Association (2008): World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr Res 100: 20–38.

    Article  PubMed  Google Scholar 

  • Tempesta E, Janiri L, Bignamini A, Chabac S, Potgieter A (2000): Acamprosate and relapse prevention in the treatment of alcohol dependence: a placebo-controlled study. Alcohol Alcohol 35: 202–209.

    CAS  PubMed  Google Scholar 

  • Thase ME (2003): Effectiveness of antidepressants: comparative remission rates. J Clin Psychiatry 64(Suppl 2): 3–7.

    CAS  Google Scholar 

  • Thase ME, Entsuah R, Rudolph RL (2001): Remission rates during treatment with ven-lafaxine or selective reuptake inhibitors. Br J Psychiatry 178: 234–241.

    Article  CAS  PubMed  Google Scholar 

  • Tohen M, Chengappa KN, Suppes T, Baker RW, Zarate CA et al (2004): Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabilizer v. mood stabilizer alone. Br J Psychiatry 184: 337–345.

    Article  PubMed  Google Scholar 

  • Trivedi MH et al. STAR*D Study Team (2006): Evaluation of outcomes with Citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 163: 28–40.

    Article  PubMed  Google Scholar 

  • Turner EH, Matthews AM, Linardatos E et al. (2008): Selective publication of antidepressant triuals and its influence on apparent efficacy. N Engl J Med 358: 252–260.

    Article  CAS  PubMed  Google Scholar 

  • Van Praag HM (2003): A stubborn behaviour: the failure of antidepressants to reduce suicide rates. World J Biol Psychiatry 4: 184–191.

    Article  PubMed  Google Scholar 

  • Volovka J, Czobor P, Cooper TB, Sheitman B, Lindenmayer JP et al. (2004): Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychiatry 65: 57–61.

    Article  Google Scholar 

  • Volz HP, Möller HJ, Reimann I, Stoll K (2000): Opipramol for the treatment of somatoform disorders. Results from a placebo-controlled trial. Eur Neuropsychophar-macol 10: 211–217.

    Article  CAS  Google Scholar 

  • Walsh BT, Seidman SN, Sysko R, Gould M (2002): Placebo response in studies of major depression. Variable, substantial and growing. JAMA 287: 1840–1847.

    Article  PubMed  Google Scholar 

  • Weinmüller B (2004): Die neuroleptische Therapie schizophrener Psychosen: eine naturalistische retrospective Untersuchung zur Behandlungswirklichkeit in einem Krankenhaus mit Vollversorgungsauftrag. Med Dissertation an der TU München. Angenommen am 15.12.2004.

    Google Scholar 

  • Wetterling T (2001): Bodyweight gain with atypical antipsychotics. A comparative review. Drug Saf 24: 59–73.

    Article  CAS  PubMed  Google Scholar 

  • Wheeler BW, Gunnell D, Metcalfe C, Stephens P, Martin RM (2008): The population impact on incidence of suicide and non-fatal selfharm of regulatory action against the use of selective serotonin reuptake inhibitors in under 18s in the United Kingdom: ecological study. Brit Med J 336: 515–516.

    Article  Google Scholar 

  • Whittington CJ, Kendall T, Fonagy P, Cottrell D, Colgrove A, Boddington E (2004): Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 363: 1341–1345.

    Article  CAS  PubMed  Google Scholar 

  • Williams JW Jr, Mulrow CD, Chiquette E, Hitchcock Noël P, Aguilar C, Cornell J (2000): Clinical guideline, part 2. A systematic review of newer pharmacotherapies for depression in adults: Evidence report summary. Ann Intern Med 132: 743–756.

    CAS  PubMed  Google Scholar 

  • Zhou S, Chan E, Pan SQ, Huang M, Lee EJ (2004): Pharmacokinetic interactions of drugs with St Johns wort. J Psychopharmacol 18: 262–276.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Pharmakologie und Toxikologie der Universität Würzburg, Versbacher Straße 9, 97078, Würzburg

    Prof. Dr. med. Martin J. Lohse

  2. Bartningallee 11-13, 10555, Berlin

    Prof. Dr. med. Bruno Müller-Oerlinghausen

Authors
  1. Prof. Dr. med. Martin J. Lohse
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. Bruno Müller-Oerlinghausen
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut der Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Ulrich Schwabe

  2. Die Gesundheitskasse, AOK Schleswig-Holstein, Edisonstraße 70, 24145, Kiel

    Dieter Paffrath

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Lohse, M.J., Müller-Oerlinghausen, B. (2008). Psychopharmaka. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2008. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-69219-5_39

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-69219-5_39

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-69218-8

  • Online ISBN: 978-3-540-69219-5

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation